Ardelyx, Inc. (ARDX)

Market Cap	893.62M
Revenue (ttm)	361.71M
Net Income (ttm)	-53.76M
Shares Out	239.26M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,002,329
Open	4.100
Previous Close	4.130
Day's Range	3.625 - 4.180
52-Week Range	3.620 - 9.330
Beta	0.76
Analysts	Strong Buy
Price Target	10.19 (+172.83%)
Earnings Date	May 1, 2025

About ARDX

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2014
• Employees: 395
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDX
• Website: https://www.ardelyx.com

Financial Performance

In 2024, Ardelyx's revenue was $333.62 million, an increase of 168.06% compared to the previous year's $124.46 million. Losses were -$39.14 million, -40.76% less than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $10.19, which is an increase of 172.83% from the latest price.

Price Target

$10.19

(172.83% upside)

Analyst Consensus: Strong Buy